JP2020506201A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506201A5 JP2020506201A5 JP2019542542A JP2019542542A JP2020506201A5 JP 2020506201 A5 JP2020506201 A5 JP 2020506201A5 JP 2019542542 A JP2019542542 A JP 2019542542A JP 2019542542 A JP2019542542 A JP 2019542542A JP 2020506201 A5 JP2020506201 A5 JP 2020506201A5
- Authority
- JP
- Japan
- Prior art keywords
- species
- antibacterial composition
- composition according
- composition
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 66
- 230000000844 anti-bacterial effect Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 20
- 241000894007 species Species 0.000 claims description 15
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 13
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 229920001451 polypropylene glycol Polymers 0.000 claims description 7
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims description 6
- 229940043353 maltol Drugs 0.000 claims description 6
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- PFPGISXUTIURGU-UHFFFAOYSA-N OC=1C(OC=CC1)=O.[Cu] Chemical compound OC=1C(OC=CC1)=O.[Cu] PFPGISXUTIURGU-UHFFFAOYSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 229940093503 ethyl maltol Drugs 0.000 claims description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 241000024378 Ilybius subtilis Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000192041 Micrococcus Species 0.000 claims 1
- 241000187528 Platypalpus luteus Species 0.000 claims 1
- 150000004699 copper complex Chemical class 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 238000010525 oxidative degradation reaction Methods 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 241000589291 Acinetobacter Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000192017 Micrococcaceae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- -1 copper hydroxypyrone compound Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1701944.9 | 2017-02-06 | ||
| GBGB1701944.9A GB201701944D0 (en) | 2017-02-06 | 2017-02-06 | Antimicrobial compositions and their uses |
| PCT/EP2018/052958 WO2018141989A1 (en) | 2017-02-06 | 2018-02-06 | Antimicrobial compositions comprising copper-hydroxypyrone complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506201A JP2020506201A (ja) | 2020-02-27 |
| JP2020506201A5 true JP2020506201A5 (enExample) | 2021-03-18 |
Family
ID=58462497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542542A Pending JP2020506201A (ja) | 2017-02-06 | 2018-02-06 | 銅−ヒドロキシピロン錯体を含む抗微生物組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11000502B2 (enExample) |
| EP (1) | EP3576730A1 (enExample) |
| JP (1) | JP2020506201A (enExample) |
| CN (1) | CN110248654A (enExample) |
| AU (1) | AU2018216241A1 (enExample) |
| BR (1) | BR112019016189A2 (enExample) |
| CA (1) | CA3051519A1 (enExample) |
| GB (1) | GB201701944D0 (enExample) |
| SG (1) | SG11201906781VA (enExample) |
| WO (1) | WO2018141989A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220175602A1 (en) * | 2019-12-02 | 2022-06-09 | Halcyon Inc. | Bedsore-preventing mattress combined with sound vibration module and air fibers, and operating method therefor |
| CN111647533A (zh) * | 2020-06-16 | 2020-09-11 | 科里思特(福建)生物科技有限公司 | 一种枯草芽孢杆菌及其制剂与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138155A (ja) * | 1993-11-12 | 1995-05-30 | Otsuka Pharmaceut Co Ltd | 抗微生物剤 |
| GB9621273D0 (en) * | 1996-10-11 | 1996-11-27 | Cortecs Ltd | Therapeutic method |
| ATE290848T1 (de) * | 1998-09-23 | 2005-04-15 | Unilever Nv | Mundpflegemittel |
| US6505233B1 (en) | 1999-08-30 | 2003-01-07 | Zaplet, Inc. | Method for communicating information among a group of participants |
| JP2002255956A (ja) * | 2001-02-27 | 2002-09-11 | Sumitomo Chem Co Ltd | 防カビ剤 |
| JP2009256228A (ja) * | 2008-04-15 | 2009-11-05 | Lion Corp | 液体口腔用組成物 |
| GB201402672D0 (en) * | 2014-02-14 | 2014-04-02 | Medical Res Council | Materials and methods relating to stabilised polymeric silicate compositions |
-
2017
- 2017-02-06 GB GBGB1701944.9A patent/GB201701944D0/en not_active Ceased
-
2018
- 2018-02-06 BR BR112019016189A patent/BR112019016189A2/pt not_active Application Discontinuation
- 2018-02-06 CA CA3051519A patent/CA3051519A1/en not_active Abandoned
- 2018-02-06 SG SG11201906781VA patent/SG11201906781VA/en unknown
- 2018-02-06 AU AU2018216241A patent/AU2018216241A1/en not_active Abandoned
- 2018-02-06 CN CN201880010474.0A patent/CN110248654A/zh active Pending
- 2018-02-06 WO PCT/EP2018/052958 patent/WO2018141989A1/en not_active Ceased
- 2018-02-06 JP JP2019542542A patent/JP2020506201A/ja active Pending
- 2018-02-06 EP EP18704508.3A patent/EP3576730A1/en not_active Withdrawn
- 2018-02-06 US US16/480,363 patent/US11000502B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9173972B2 (en) | Methods and compositions for promoting wound healing | |
| US6017912A (en) | Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle | |
| JP2009502965A (ja) | 細菌を処置するための組成物および方法 | |
| Marone et al. | Comparative in vitro activity of silver sulfadiazine, alone and in combination with cerium nitrate, against staphylococci and gram-negative bacteria | |
| Lio et al. | Topical antibacterial agents | |
| US5912255A (en) | Topical fluoroquinolone antibiotics combined with benzoyl peroxide | |
| WO2012017349A3 (en) | Topical pharmaceutical composition comprising nanonized silver sulfadiazine and chlorhexidine gluconate | |
| JP2020506201A5 (enExample) | ||
| WO2003039559B1 (en) | Pharmaceutical combinatons comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application | |
| US20030171340A1 (en) | Methods of disease treatment using metal-complexed tetracycline antibiotics | |
| Fasina et al. | Significance of endogenous antimicrobial peptides on the health of food animals | |
| US20040247696A1 (en) | Methods of using electron active compounds for managing conditions afflicting mammals | |
| CN100384422C (zh) | 包含金属离子螯合剂的抗微生物组合物 | |
| Eskandari et al. | Antimicrobial and antibiofilm activity of prepared thymol@ UIO-66 and thymol/ZnONPs@ UIO-66 nanoparticles against Methicillin-resistant Staphylococcus aureus: A synergistic approach | |
| EP1585506A1 (en) | Methods and compositions for wound management | |
| Roosendaal et al. | Impact of the antibiotic dosage schedule on efficacy in experimental lung infections | |
| KR20160126004A (ko) | 항세균제를 포함하는 제약학적 조성물 | |
| WO2003070231A1 (en) | Antibacterial compositions | |
| Ivantsyk et al. | Advantages of the composition and actyvity of a new combined ointment with ethony for treatment of the wound process | |
| Jasuja et al. | Bacteriology of primary pyodermas and comparative efficacy of topical application of mupirocin and sodium fusidate ointments in their treatment | |
| RU2800585C1 (ru) | Способ лечения бордетеллезной пневмонии поросят | |
| EP4267146B1 (en) | An orthosomycin antimicrobial compound for use in methods of treating mastitis | |
| Van Nguyen et al. | Antibacterial Activity and Interaction Effects of Litsea Cubeba Fruit Essential Oil and Chitosan Against Food-Borne Bacteria | |
| WO2025186334A8 (en) | Lipidic alkynylcarbinols with anti-bacterial and anti-tuberculosis activity | |
| Collins et al. | CUTIS Do Not Copy |